FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2549541024> ?p ?o ?g. }

• W2549541024 endingPage "1952" @default.
• W2549541024 startingPage "1952" @default.
• W2549541024 abstract "Abstract Abstract 1952 Background: Initial clinical response rates have improved significantly with current treatments for multiple myeloma (MM). However, most patients eventually relapse or become refractory to approved agents, prompting the development of additional targeted agents and combination regimens. Vorinostat is a first-in-class oral histone deacetylase inhibitor that regulates the expression of genes and proteins involved in tumor growth and survival, and is approved in the United States for the treatment of patients with advanced cutaneous T-cell lymphoma in whom prior therapies have failed. Bortezomib, a reversible proteasome inhibitor, is approved for the treatment of patients with MM who have received at least 1 prior therapy. The synergistic effects of vorinostat and bortezomib have been shown in preclinical studies and confirmed in Phase I trials in patients with relapsed/refractory (RR) MM, producing objective response rates (ORRs; partial response or better) of up to 42% in all patients (including those with bortezomib-refractory disease) and overall clinical benefit of up to 90%. Methods: Vantage 088 is a global, Phase III, randomized, double-blind study to investigate the safety and efficacy of vorinostat vs placebo in combination with bortezomib in patients with relapsed MM and progressive disease after 1–3 prior antimyeloma regimens. The primary objective is to determine the duration of progression-free survival, with a planned enrollment of 742 patients. Overall survival, time to progression, ORR, tolerability, and patient-reported outcomes (PROs) will be included as secondary and exploratory outcomes. A distinctive aspect of this study design involves the evaluation of PROs using validated instruments, including quality-of-life (QoL) questionnaires for cancer patients (EORTC QLQ-C30) and myeloma patients (EORTC QLQ-MY20) and the EuroQoL-5D, presenting an opportunity to correlate PROs with efficacy and safety data. Interim analysis will take place when at least 126 events have occurred. Vantage 095 is a Phase IIB open-label study to investigate the efficacy and tolerability of vorinostat combined with bortezomib in patients with RR MM who had received ≥2 prior antimyeloma regimens; were refractory to bortezomib; and were relapsed, refractory to, intolerant of, or ineligible for other MM therapies, including immunomodulatory drugs (IMiDs). The primary objective is to determine the ORR, with a planned enrollment of 142 patients. In both studies, patients receive 21-day cycles of intravenous bortezomib (1.3 mg/m2; days 1, 4, 8, and 11) combined with oral vorinostat 400 mg (or matching placebo in Vantage 088) once daily on days 1–14. Efficacy is assessed using European Bone and Marrow Transplantation Group criteria. Adverse events (AEs; including clinical and laboratory events) are assessed and recorded using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0). Results: Vantage 088: As of June 11, 2010, 349 patients (range, 1–17 cycles) were randomized. Patients received a median of 2 prior regimens (range, 1–3 regimens; 25% prior bortezomib, 48% prior thalidomide, and 12% prior lenalidomide). Vantage 095: As of June 11, 2010, 108 patients were enrolled. Patients (median age, 62 y; 57% men; 67% with Eastern Cooperative Oncology Group performance status 1) were heavily pretreated (median prior regimens, 5 [range, 2–17]). Interim efficacy data were reviewed in January 2010 by an independent data monitoring committee (DMC) for the first 43 patients enrolled; the futility threshold was passed, and final results are expected to be available 2Q2011. Conclusion: 2 ongoing global, multicenter, investigational trials are evaluating the efficacy and safety of combined vorinostat and bortezomib in patients with RR MM and are rapidly accruing patients. The Vantage 088 trial has passed the initial safety evaluations by the DMC, while interim results from Vantage 095 suggest that combined vorinostat and bortezomib may have clinical activity in patients with RR MM who are refractory to bortezomib and IMiDs and ineligible for other regimens. Disclosures: Siegel: Celgene and Millennium: Advisory Board, Speakers Bureau; Merck: Advisory Board, Consultancy. Off Label Use: Vorinostat Combined with Bortezomib for treatment in Multiple Myeloma. Jagannath:Celgene: Honoraria; Millenium: Honoraria; Ortho Biotech: Honoraria; Onyx Pharma: Honoraria; Merck: Honoraria; Proteolix: Honoraria; Imedex: Speakers Bureau; Medicom World Wide: Speakers Bureau; Optum Health Education: Speakers Bureau; PER Group: Speakers Bureau. Hajek:Janssen-Cilag: Honoraria; Celgene: Honoraria; Merck, Sharp, and Dohme: Honoraria. Dimopoulos:MSD: Honoraria, Membership on an entity's Board of Directors or advisory committees; Millenium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Ortho Biotech: Honoraria, Membership on an entity's Board of Directors or advisory committees. Lonial:Millennium: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; BMS: Consultancy, Research Funding; Novartis: Consultancy, Research Funding; Onyx: Consultancy, Research Funding. Graef:Merck Research Laboratories: Employment. Pietrangelo:Merck Research Laboratories: Employment. Lupinacci:Merck Research Laboratories: Employment. Reiser:Merck Research Laboratories: Employment. Anderson:Millennium Pharmaceuticals: Consultancy; Celgene: Consultancy; Novartis: Consultancy; Onyx: Consultancy; Merck: Consultancy; BMS: Consultancy; Acetylon: Equity Ownership, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau." @default.
• W2549541024 created "2016-11-30" @default.
• W2549541024 creator A5008279667 @default.
• W2549541024 creator A5012405296 @default.
• W2549541024 creator A5015768490 @default.
• W2549541024 creator A5023276777 @default.
• W2549541024 creator A5023752321 @default.
• W2549541024 creator A5028046297 @default.
• W2549541024 creator A5032464400 @default.
• W2549541024 creator A5045593405 @default.
• W2549541024 creator A5049711954 @default.
• W2549541024 creator A5055012214 @default.
• W2549541024 creator A5065779804 @default.
• W2549541024 creator A5090512266 @default.
• W2549541024 date "2010-11-19" @default.
• W2549541024 modified "2023-10-18" @default.
• W2549541024 title "Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program" @default.
• W2549541024 doi "https://doi.org/10.1182/blood.v116.21.1952.1952" @default.
• W2549541024 hasPublicationYear "2010" @default.
• W2549541024 type Work @default.
• W2549541024 sameAs 2549541024 @default.
• W2549541024 citedByCount "3" @default.
• W2549541024 countsByYear W25495410242012 @default.
• W2549541024 crossrefType "journal-article" @default.
• W2549541024 hasAuthorship W2549541024A5008279667 @default.
• W2549541024 hasAuthorship W2549541024A5012405296 @default.
• W2549541024 hasAuthorship W2549541024A5015768490 @default.
• W2549541024 hasAuthorship W2549541024A5023276777 @default.
• W2549541024 hasAuthorship W2549541024A5023752321 @default.
• W2549541024 hasAuthorship W2549541024A5028046297 @default.
• W2549541024 hasAuthorship W2549541024A5032464400 @default.
• W2549541024 hasAuthorship W2549541024A5045593405 @default.
• W2549541024 hasAuthorship W2549541024A5049711954 @default.
• W2549541024 hasAuthorship W2549541024A5055012214 @default.
• W2549541024 hasAuthorship W2549541024A5065779804 @default.
• W2549541024 hasAuthorship W2549541024A5090512266 @default.
• W2549541024 hasConcept C104317684 @default.
• W2549541024 hasConcept C121332964 @default.
• W2549541024 hasConcept C126322002 @default.
• W2549541024 hasConcept C142424586 @default.
• W2549541024 hasConcept C143998085 @default.
• W2549541024 hasConcept C185592680 @default.
• W2549541024 hasConcept C197934379 @default.
• W2549541024 hasConcept C2776262904 @default.
• W2549541024 hasConcept C2776364478 @default.
• W2549541024 hasConcept C2776694085 @default.
• W2549541024 hasConcept C2777478702 @default.
• W2549541024 hasConcept C2778305200 @default.
• W2549541024 hasConcept C2778367456 @default.
• W2549541024 hasConcept C2778375690 @default.
• W2549541024 hasConcept C2778822529 @default.
• W2549541024 hasConcept C2781462825 @default.
• W2549541024 hasConcept C31760486 @default.
• W2549541024 hasConcept C535046627 @default.
• W2549541024 hasConcept C55493867 @default.
• W2549541024 hasConcept C64927066 @default.
• W2549541024 hasConcept C71924100 @default.
• W2549541024 hasConcept C87355193 @default.
• W2549541024 hasConceptScore W2549541024C104317684 @default.
• W2549541024 hasConceptScore W2549541024C121332964 @default.
• W2549541024 hasConceptScore W2549541024C126322002 @default.
• W2549541024 hasConceptScore W2549541024C142424586 @default.
• W2549541024 hasConceptScore W2549541024C143998085 @default.
• W2549541024 hasConceptScore W2549541024C185592680 @default.
• W2549541024 hasConceptScore W2549541024C197934379 @default.
• W2549541024 hasConceptScore W2549541024C2776262904 @default.
• W2549541024 hasConceptScore W2549541024C2776364478 @default.
• W2549541024 hasConceptScore W2549541024C2776694085 @default.
• W2549541024 hasConceptScore W2549541024C2777478702 @default.
• W2549541024 hasConceptScore W2549541024C2778305200 @default.
• W2549541024 hasConceptScore W2549541024C2778367456 @default.
• W2549541024 hasConceptScore W2549541024C2778375690 @default.
• W2549541024 hasConceptScore W2549541024C2778822529 @default.
• W2549541024 hasConceptScore W2549541024C2781462825 @default.
• W2549541024 hasConceptScore W2549541024C31760486 @default.
• W2549541024 hasConceptScore W2549541024C535046627 @default.
• W2549541024 hasConceptScore W2549541024C55493867 @default.
• W2549541024 hasConceptScore W2549541024C64927066 @default.
• W2549541024 hasConceptScore W2549541024C71924100 @default.
• W2549541024 hasConceptScore W2549541024C87355193 @default.
• W2549541024 hasIssue "21" @default.
• W2549541024 hasLocation W25495410241 @default.
• W2549541024 hasOpenAccess W2549541024 @default.
• W2549541024 hasPrimaryLocation W25495410241 @default.
• W2549541024 hasRelatedWork W2004252053 @default.
• W2549541024 hasRelatedWork W2076028786 @default.
• W2549541024 hasRelatedWork W2124426490 @default.
• W2549541024 hasRelatedWork W2147486721 @default.
• W2549541024 hasRelatedWork W2499238458 @default.
• W2549541024 hasRelatedWork W2536959366 @default.
• W2549541024 hasRelatedWork W2549541024 @default.
• W2549541024 hasRelatedWork W2572418348 @default.
• W2549541024 hasRelatedWork W2915861299 @default.
• W2549541024 hasRelatedWork W2979590512 @default.
• W2549541024 hasVolume "116" @default.
• W2549541024 isParatext "false" @default.
• W2549541024 isRetracted "false" @default.
• W2549541024 magId "2549541024" @default.

• next